Page results
-
UCLH is the first NHS trust to pilot a personalised educational package for patients living with stroke.
-
UCLH has recruited the first participant for a new UK based study for Parkinson’s Disease (PD). The ASPro-PD study is testing whether treatment with a drug called ambroxol is associated with an improvement in motor and non-motor function compared with placebo.
-
UCLH will play a vital role in a new respiratory virus study.
-
RNOH are pleased to launch a series of regular Health and Wellbeing Information and Support Sessions to support patients following a cancer diagnosis and also during/after treatment. These…
-
Martin Jacobs joined UCLH as a non-executive director on 1 January 2020. He spent 20 years with PricewaterhouseCoopers (PwC) where he was a Partner within the Corporate Finance division.
-
Five UCLH consultants have been elected Fellows of the Academy of Medical Sciences in recognition of their exceptional contributions to biomedical and health science and their ability to generate new knowledge and improve the health of people everywhere.
-
UCLH is reminding staff that gloves are not always required, by reducing the instances where non-sterile plastic gloves are used when treating non-infectious patients. The focus is now on how clean hands are just as effective a barrier against infection.
-
All medications given to you while you are an inpatient are provided free of charge. At follow-up appointments, you may be given a prescription by your doctor or nurse. This must be collected from the hospital pharmacy; you cannot take it to your local chemist. There is a standard prescription charge per item which you can pay for by cash or card.
-
Until this point, if a largely over estimated total daily dose was entered by the user incorrectly, there is a risk of over delivery of insulin during Auto mode. This risk is the highest on the first day and reduces gradually over subsequent days.
File results
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services
-
FOI/2022/0226 - Treatments for Haemophilia A
-
FOI/2022/0227 - Number of cancer trackers and cancer MDT co-ordinators at Trust
-
FOI/2022/0230 - Fabry, Gaucher and Pompe diseases drug treatments
-
FOI/2022/0232 - Number of patients who have died while waiting for elective care
-
FOI/2022/0233 - Diagnosis/ treatment of epilepsy, dravet syndrome, lennox gastaut syndrome and tuberous sclerosis complex